Search
Ketobemidone
go.drugbank.com/drugs/DB06738InvestigationalThe most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids.
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalIt is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. … An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties.
Mixtures: ESTELLE-35 ED TABLET, CLIMEN 2MG+ 2MG/1 MG KAPLI TABLET, 21 ADETProducts: ANDROCUR 10 MG, ONCOTERONA® 50 MGAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing
Pantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalat the secretory surface of gastric parietal cell. … It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example.
Products: PANTOPRAZOLO EG, PANTO 40 MG IV ENJ. LIYOFILIZE TOZ ICEREN FLAKONPixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnPixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL. … Pixantrone was designed to treat relapsed or refractory aggressive non-Hodgkin's lymphoma(NHL) in patients who have failed two prior lines of therapy. [2] For patients suffering from NHL, first line therapies
Mepyramine
go.drugbank.com/drugs/DB06691ApprovedVet approvedIt has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. … It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect.
Mixtures: PAMACET 500 MG/25 MG/15 MG FİLM KAPLI TABLET, 24 ADET, PAMACET 500 MG/25 MG/15 MG FİLM KAPLI TABLET, 40 ADETCategories: Antihistamines, Anesthetics, Etc.Beractant
go.drugbank.com/drugs/DB06761ApprovedThe final composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL … It is suspended in 0.9% sodium chloride solution, and heat-sterilized.
Products: Alveofact 45 mg/ml Pulver und Lösungsmittel zur Herstellung einer Suspension zur endotracheopulmonalen InstillationMeropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalIt is active against Gram-positive and Gram-negative bacteria. … In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI).
Synonyms: (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidProducts: MERONEM 500 MG IV ENJ. ICIN TOZ ICEREN FLAKON, 1 ADET, MERONEM 1 GR IV ENJ. ICIN TOZ ICEREN FLAKON, 1 ADETSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalMost recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953] … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors … [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression
Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine